AN2 Therapeutics Inc expected to post a loss of 33 cents a share - Earnings Preview

AN2 Therapeutics

30/07/2025 21:10

AN2 Therapeutics Inc ANTX.OQ ANTX.O is expected to  show no change in quarterly revenue when it reports  results on August 1 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for AN2 Therapeutics Inc is for a loss of 33 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for AN2 Therapeutics Inc is $2.00, about 46% above its last closing price of $1.08

This summary was machine generated July 30 at 20:10 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)